ENN
0.057
35.7%
MAP
0.045
-28.6%
CAN
0.004
33.3%
HYD
0.003
-25%
SMS
0.049
32.4%
NES
0.003
-25%
BST
0.7
28.4%
AMD
0.004
-20%
EG1
0.023
21.1%
CLA
0.004
-20%
EMT
0.006
20%
GHY
0.4
-16.7%
R8R
0.155
19.2%
KNG
0.05
-16.7%
CAZ
0.019
18.8%
AVD
0.15
-14.3%
RR1
0.013
18.2%
PL9
0.006
-14.3%
LTP
0.585
17%
VFY
3.3
-13.2%
BNL
0.007
16.7%
DTR
0.115
-11.5%
CSX
0.42
16.7%
STM
0.245
-10.9%
EPM
0.014
16.7%
VTX
0.112
-10.4%
FRB
0.175
16.7%
SIX
0.053
-10.2%
NSB
0.07
16.7%
CMO
0.009
-10%
KZR
0.145
16%
MOH
0.009
-10%
BMC
3.05
16%
NZK
0.18
-10%
ICE
0.039
14.7%
CKA
0.047
-9.6%
ATH
0.51
14.6%
TOE
0.47
-9.6%
LU7
0.008
14.3%
RGL
0.011
-8.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BOT successful completion of human factors validation study

Clinical dermatology company Botanix Pharmaceuticals (ASX:BOT) announces that the Company has successfully completed the planned human factors validation study assessing the revised Instructions for Use for Sofpironium Bromide gel https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02753854-6A1186430 #shorts